| Autor: |
Jafarian, Amir Hossein, Nasirabadi, Khatoone Mirshekar, Etemad, Sare, Jafaripour, Masoumeh, Darijani, Mansoore, Sheikhi, Maryam, Ayatollahi, Hossein, Shakeri, Sepideh, Shams, Seyyede Fatemeh, Davari, Saeed |
| Předmět: |
|
| Zdroj: |
Iranian Journal of Pathology; Fall2018, Vol. 13 Issue 4, p415-421, 7p |
| Abstrakt: |
Background and Objective: BRAF mutations were studied in various populations for prostate carcinoma (PC); however, mutations in BRAF gene are unusual compared to KRAS. Oncogenic activating of BRAF mutations were studied lately in almost 0%- 10% of prostate cancer cases. Methods: In this retrospective study, we gathered 100 formalin-fixed paraffin-embedded samples of prostate adenocarcinoma. A hundred archived samples of adjacent benign prostatic hyperplasia were chosen as normal control. This study was done in pathology laboratory of Qaem Hospital during 2013-2015. Results: Total number of 200 PC and normal cases was investigated for BRAF V600E mutation. The BRAF V600E mutation was found in only 4 patients but it was not detected in normal cases. There were no significant differences between patient and control groups for this mutation (P>0.99). The frequency of BRAF V600E mutation was not significant in different age groups (P>0.285); the most frequency was related to the age range of 71-80. No significant difference was observed between tumor grade and BRAF mutation (P=0.21). Conclusion: According to our findings, BRAF gene mutations did not play essential role in PC. Therefore, anti-BRAF (V600E) could not be considered as a proper target for therapy. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
